PharmaCell to Finalize Purchase of Cell Therapy Production Facility

Published on: 

PharmaCell has finalized its purchase of the cell therapy production facility from TiGenix.

PharmaCell, a CMO for cellular therapies and regenerative medicine in Europe, has finalized its purchase of the cell therapy production facility from TiGenix, a cell therapy company. TiGenix has manufactured ChondroCelect, a product for cartilage repair, at its site in Sittard-Geleen, The Netherlands, since the beginning of 2013. ChondroCelect will continue to be manufactured at the facility as before under a long-term CMO agreement with TiGenix.

Following the acquisition, PharmaCell will continue to operate its Maastricht facility in addition to the site at Sittard-Geleen. The Maastricht facility offers non-GMP process development and GMP-production facilities for early- to mid-stage clinical trials in cell therapy. The Geleen facility will offer clients the opportunity to support late stage clinical trials and commercial production for the industry.

Advertisement

Source: PharmaCell